Cargando…

Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors

Classical Philadelphia- negative myeloproliferative neoplasms (MPNs) encompass three main myeloid malignancies: polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF). Phenotype-driver mutations in Janus kinase 2 (JAK2), calreticulin (CALR), and myeloproliferative leukemia vi...

Descripción completa

Detalles Bibliográficos
Autor principal:	Helbig, Grzegorz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096973/ https://www.ncbi.nlm.nih.gov/pubmed/30074114 http://dx.doi.org/10.1007/s12032-018-1187-3

Ejemplares similares

Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms
por: Kaplan, Jason B., et al.
Publicado: (2016)

Philadelphia-negative chronic myeloproliferative neoplasms
por: Bittencourt, Rosane Isabel, et al.
Publicado: (2012)

The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms
por: Wu, Zhiyuan, et al.
Publicado: (2014)

Effects of Mutational Combinations on Philadelphia-Negative Myeloproliferative Neoplasms
por: Ipek, Yonal-Hindilerden, et al.
Publicado: (2017)

Molecular biology of Philadelphia-negative myeloproliferative neoplasms
por: Campregher, Paulo Vidal, et al.
Publicado: (2012)

Ocular Manifestations in Patients with Philadelphia-Negative Myeloproliferative Neoplasms
por: Liisborg, Charlotte, et al.
Publicado: (2020)

Applications of Artificial Intelligence in Philadelphia-Negative Myeloproliferative Neoplasms
por: Elsayed, Basel, et al.
Publicado: (2023)

Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms
por: Singdong, Roongrudee, et al.
Publicado: (2016)

Inflammatory picture of Philadelphia-negative myeloproliferative neoplasms()
por: Pagnano, Katia Borgia Barbosa
Publicado: (2018)

Clinical Impact of JAK2V617F Allele Burden in Philadelphia-Negative Myeloproliferative Neoplasms
por: Yönal-Hindilerden, İpek, et al.
Publicado: (2023)

The Prognostic Role of Cytogenetics Analysis in Philadelphia Negative Myeloproliferative Neoplasms
por: Lanzarone, Giuseppe, et al.
Publicado: (2021)

The Role of Neutrophilic Granulocytes in Philadelphia Chromosome Negative Myeloproliferative Neoplasms
por: Kiem, Dominik, et al.
Publicado: (2021)

Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms
por: Stuckey, Ruth, et al.
Publicado: (2023)

The clinical role of interferon alpha in Philadelphia-negative myeloproliferative neoplasms
por: Yoon, Seug Yun, et al.
Publicado: (2021)

Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature
por: Yadav, Ruchi, et al.
Publicado: (2023)

Splenic Infarction in Patients with Philadelphia-negative Myeloproliferative Neoplasms
por: Lee, Myung-Won, et al.
Publicado: (2022)

Philadelphia‐negative myeloproliferative neoplasms among Kuwaiti Nationals
por: Alshemmari, Salem, et al.
Publicado: (2020)

Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms
por: Yung, Yammy, et al.
Publicado: (2021)

Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies
por: Passamonti, Francesco, et al.
Publicado: (2011)

Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms
por: Holmström, Morten Orebo, et al.
Publicado: (2020)

Primary Arterial Hypertension and Drug-Induced Hypertension in Philadelphia-Negative Classical Myeloproliferative Neoplasms: A Systematic Review
por: Găman, Mihnea-Alexandru, et al.
Publicado: (2023)

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders
por: Vainchenker, William, et al.
Publicado: (2018)

Relationship of JAK2 (V617F) Allelic Burden with Clinico-Haematological Manifestations of Philadelphia-Negative Myeloproliferative Neoplasms
por: Yow, Ka Shing, et al.
Publicado: (2020)

Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms
por: Yonal-Hindilerden, Ipek, et al.
Publicado: (2015)

Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation
por: Cacemiro, Maira da Costa, et al.
Publicado: (2018)

The Association Between JAK2V617F Mutation and Bone Marrow Fibrosis at Diagnosis in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms
por: Arı, M. Cem, et al.
Publicado: (2012)

Evaluation of the JAK2V617F Mutational Burden in Patients with Philadelphia Chromosome Negative Myeloproliferative Neoplasms: A Single-center Experience
por: Popova-Labachevska, M, et al.
Publicado: (2019)

Genetic and Clinical Characteristics of Patients with Philadelphia-Negative Myeloproliferative Neoplasm Carrying Concurrent Mutations in JAK2V617F, CALR, and MPL
por: Wang, Yan, et al.
Publicado: (2023)

Philadelphia-Negative Myeloproliferative Neoplasms Around the COVID-19 Pandemic
por: Barbui, Tiziano, et al.
Publicado: (2021)

Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms
por: Pandey, Ruchi, et al.
Publicado: (2015)

Liquid Biopsy and Potential Liquid Biopsy-Based Biomarkers in Philadelphia-Negative Classical Myeloproliferative Neoplasms: A Systematic Review
por: Găman, Mihnea-Alexandru, et al.
Publicado: (2021)

The allele burden of JAK2 V617F can aid in differential diagnosis of Philadelphia Chromosome-Negative Myeloproliferative Neoplasm
por: Park, Sang Hyuk, et al.
Publicado: (2013)

CCL2 rs1024611Gene Polymorphism in Philadelphia-Negative Myeloproliferative Neoplasms
por: Hodeib, Hossam, et al.
Publicado: (2022)

The Genomic Landscape in Philadelphia-Negative Myeloproliferative Neoplasm Patients with Second Cancers
por: Hsu, Chia-Chen, et al.
Publicado: (2022)

Acquired von willebrand syndrome in patients with Philadelphia-negative myeloproliferative neoplasm
por: Song, Ik-Chan, et al.
Publicado: (2023)

Platelets Contribution to Thrombin Generation in Philadelphia-Negative Myeloproliferative Neoplasms: The “Circulating Wound” Model
por: Lucchesi, Alessandro, et al.
Publicado: (2021)

Erratum on “Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation”
por: Cacemiro, Maira da Costa, et al.
Publicado: (2021)

Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms
por: Mora, Barbara, et al.
Publicado: (2022)

Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis
por: Loscocco, Giuseppe G., et al.
Publicado: (2022)

Pediatric Philadelphia-Negative Myeloproliferative Neoplasms in the Era of WHO Classification: A Systematic Review
por: Al-Mashdali, Abdulrahman F., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3uhr2d21qf4c8em0els753fip4